Optimal risk factor modification and medical management of the patient with peripheral arterial disease

被引:36
作者
Chi, Yung-Wei [1 ]
Jaff, Michael R. [2 ]
机构
[1] Ochsner Clin Fdn, Ochsner Heatr & Vasc Inst, Dept Cardiol, Sect Vasc Med, New Orleans, LA USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Vasc Med, Boston, MA USA
关键词
medical management; peripheral arterial occlusive disease; risk factor modification;
D O I
10.1002/ccd.21401
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Peripheral arterial occlusive disease (PAD) is a highly prevalent atherosclerotic syndrome associated with significant morbidity and mortality. It is defined by atherosclerotic obstruction of the abdominal aorta and arteries to the legs that reduces arterial flow during exercise and/or at rest, and is a common manifestation of systemic atherosclerosis. PAD represents a marker for premature cardiovascular events, and in patients with PAD, even in the absence of a history of myocardial infarction (MI) or ischemic stroke, they have approximately the same relative risk of death from cardiovascular causes as do patients with a history of coronary or cerebrovascular disease. In addition, their death rate from all causes is approximately equal in men and women and is elevated even in asymptomatic patients. The major risk factors for PAD are the well defined atherosclerotic risks such as diabetes mellitus, cigarette smoking, advanced age, hyperlipidemia, and hypertension. Due to the presence of these risk factors, the systemic nature of atherosclerosis, and the high risk of ischemic events, patients with PAD should be candidates for aggressive secondary prevention strategies including aggressive risk factor modification, antiplatelet therapy, lipid lowering therapy and antihypertensive treatment. This article reviews the current medical treatment and risk factor modification of patients with PAD. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:475 / 489
页数:15
相关论文
共 131 条
  • [1] RETRACTED: Brief communication: Ramipril markedly improves walking ability in patients with peripheral arterial disease - A randomized trial (Retracted article)
    Ahimastos, AA
    Lawler, A
    Reid, CM
    Blombery, PA
    Kingwell, BA
    [J]. ANNALS OF INTERNAL MEDICINE, 2006, 144 (09) : 660 - 664
  • [2] [Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]
  • [3] [Anonymous], JAMA
  • [4] [Anonymous], 2002, COCHRANE DB SYST REV
  • [5] *ANT TRIAL COLL, 2002, BMJ-BRIT MED J, V12, P324
  • [6] Effect of Simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment
    Aronow, WS
    Nayak, D
    Woodworth, S
    Ahn, C
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (06) : 711 - 712
  • [7] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [8] BAZZANO LA, 2007, JAMA-J AM MED ASSOC, V297, P952
  • [9] Effect of folic acid supplementation on risk of cardiovascular diseases - A meta-analysis of randomized controlled trials
    Bazzano, Lydia A.
    Reynolds, Kristi
    Holder, Kevin N.
    He, Jiang
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (22): : 2720 - 2726
  • [10] The importance of increasing public and physician awareness of peripheral arterial disease
    Becker, GJ
    McClenny, TE
    Kovacs, ME
    Raabe, RD
    Katzen, BT
    [J]. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2002, 13 (01) : 7 - 11